Merck: wins first patent litigation battle
(CercleFinance.com) - Merck today announced that the US District Court for the Northern District of West Virginia has ruled in its favour in a patent infringement suit filed against Viatris involving sitagliptin, an active ingredient in Januvia, Janumet and Janumet XR.
Merck brought infringement actions against Viatris under both patents, for which Viatris alleged non-infringement and/or invalidity.
The Court found that both of Merck's patents at issue were valid and had been infringed. However, the decision is subject to appeal.
In addition, Merck announced that it has entered into patent settlement agreements with several generic companies, enabling them to market their generic versions of Januvia and Janumet in the US from May 2026 or earlier under certain circumstances, and generic versions of Janumet XR in July 2026 or earlier under certain circumstances.
Copyright (c) 2022 CercleFinance.com. All rights reserved.